Metabolic Disorders
GlobalData’s reports offer expert analysis, insights and opinions to companies in the world’s largest industries. Explore unique market-leading data today and benefit from access to actionable insight within the Metabolic Disorders market. Reports cover market growth forecasts, trends and research, and more.
Browse our full list of Metabolic Disorders market reports here.
- Currency Conversion is for Indicative purpose only. All orders are processed in US Dollars only.
- USD - US Dollar
- AUD — Australian Dollar
- BRL — Brazilian Real
- CNY — Yuan Renminbi
- EUR — Euro
- GBP — Pound Sterling
- INR — Indian Rupee
- JPY — Japanese Yen
- ZAR — South African Rand
- The Price Conversion is only for the Indicative purpose.
- USD — US Dollar
- AUD — Australian Dollar
- BRL — Brazilian Real
- CNY — Yuan Renminbi
- EUR — Euro
- GBP — Pound Sterling
- INR — Indian Rupee
- JPY — Japanese Yen
- ZAR — South African Rand
-
Product Insights
Non-Proliferative Diabetic Retinopathy (NPDR) Global Clinical Trials Review, H1, 2018 Non-Proliferative Diabetic Retinopathy (NPDR) Global Clinical Trials Review, H1, 2018
$2,500 | March 2018 GlobalData's clinical trial report, “Non-Proliferative Diabetic Retinopathy (NPDR) Global Clinical Trials Review, H1, 2018" provides an overview of Non-Proliferative Diabetic Retinopathy (NPDR) clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Proliferative Diabetic Retinopathy (NPDR). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Product Insights
Pompe Disease - Global Clinical Trials Review, H2, 2020 Pompe Disease - Global Clinical Trials Review, H2, 2020
$2,500 | December 2020 GlobalData's clinical trial report, “Pompe Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Pompe Disease Clinical trials scenario. This report provides top line data relating to the clinical trials on Pompe Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides...
-
Product Insights
Diabetic Foot Infection (DFI) - Global Clinical Trials Review, H1, 2021 Diabetic Foot Infection (DFI) - Global Clinical Trials Review, H1, 2021
$2,500 | June 2021 GlobalData's clinical trial report, “Diabetic Foot Infection (DFI) - Global Clinical Trials Review, H1, 2021" provides an overview of Diabetic Foot Infection (DFI) Clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Foot Infection (DFI). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status...
-
Product Insights
Hyperinsulinemia - Global Clinical Trials Review, H1, 2021 Hyperinsulinemia - Global Clinical Trials Review, H1, 2021
$2,500 | June 2021 GlobalData's clinical trial report, “Hyperinsulinemia - Global Clinical Trials Review, H1, 2021" provides an overview of Hyperinsulinemia Clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperinsulinemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for...
-
Sector Analysis
Dyslipidemia - Competitive Landscape in 2021 Dyslipidemia - Competitive Landscape in 2021
$3,495 | June 2021 In dyslipidemia 3 hydroxy 3 methylglutaryl coenzyme a (HMG CoA) reductase is a major focus of drug developers. There are 155 drugs in the pipeline with 74% molecules present in early stage. Mid-sized Pharma dominates R&D in this indication. The increasing prevalence and preference for newer expensive therapies will drive the market's growth, but delayed diagnosis, low compliance rate, and high preference for low-cost generic products are likely to limit market growth.
-
Product Insights
Diabetic Foot Infection (DFI) Disease - Global Clinical Trials Review, H2, 2020 Diabetic Foot Infection (DFI) Disease - Global Clinical Trials Review, H2, 2020
$2,500 | November 2020 GlobalData's clinical trial report, “Diabetic Foot Infection (DFI) Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Diabetic Foot Infection (DFI) Clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Foot Infection (DFI). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points...
-
Product Insights
Diabetic Peripheral Neuropathy Disease - Global Clinical Trials Review, H2, 2020 Diabetic Peripheral Neuropathy Disease - Global Clinical Trials Review, H2, 2020
$2,500 | December 2020 GlobalData's clinical trial report, “Diabetic Peripheral Neuropathy Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Diabetic Peripheral Neuropathy Clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Peripheral Neuropathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor...
-
Sector Analysis
Hypoglycemia - Epidemiology Forecast to 2030 Hypoglycemia - Epidemiology Forecast to 2030
$3,995 | November 2021 Hypoglycemia is a condition in which a person’s glucose, or blood sugar, level is lower than normal. It most often, although not exclusively, occurs in patients with drug-treated type 1 (T1D) or type 2 diabetes mellitus (T2D), as glucose-lowering medications can lead to hypoglycemia (Silbert et al., 2018). Symptoms of hypoglycemia include fatigue, fast heartbeat, shakiness, anxiety, and hunger. During a severe hypoglycemic episode, symptoms can escalate to blurred vision, confusion, seizures, or even loss of consciousness. In those without...
-
Product Insights
Homozygous Familial Hypercholesterolemia (HoFH) - Global Clinical Trials Review, H2, 2021 Homozygous Familial Hypercholesterolemia (HoFH) - Global Clinical Trials Review, H2, 2021
$2,500 | November 2021 GlobalData's clinical trial report provides an overview of the homozygous familial hypercholesterolemia (hofh) clinical trials scenario. This report provides top-line data relating to the clinical trials on homozygous familial hypercholesterolemia. The report includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type. The report also provides prominent drugs for in-progress...
-
Product Insights
Diabetic Nephropathy Disease - Global Clinical Trials Review, H1 2020 Diabetic Nephropathy Disease - Global Clinical Trials Review, H1 2020
$2,500 | March 2020 GlobalData's clinical trial report, “Diabetic Nephropathy Global Clinical Trials Review, H1, 2020" provides an overview of Diabetic Nephropathy Clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Nephropathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.